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Abstract
Background: The PTEN tumour suppressor gene and PIK3CA proto-oncogene encode proteins which contribute to
regulation and propagation of signal transduction through the PI3K/AKT signalling pathway. This study investigates
the prevalence of loss of PTEN expression and mutations in both PTEN and PIK3CA in colorectal cancers (CRC) and
their associations with tumour clinicopathological features, lifestyle factors and dietary consumptions.
Methods: 186 adenocarcinomas and 16 adenomas from the EPIC Norfolk study were tested for PTEN and PIK3CA
mutations by DNA sequencing and PTEN expression changes by immunohistochemistry. Dietary and lifestyle data
were collected prospectively using seven day food diaries and lifestyle questionnaires.
Results: Mutations in exons 7 and 8 of PTEN were observed in 2.2% of CRC and PTEN loss of expression was
identified in 34.9% CRC. Negative PTEN expression was associated with lower blood low-density lipoprotein
concentrations (p = 0.05). PIK3CA mutations were observed in 7% of cancers and were more frequent in CRCs in
females (p = 0.04). Analysis of dietary intakes demonstrated no link between PTEN expression status and any
specific dietary factor. PTEN expression negative, proximal CRC were of more advanced Dukes’ stage (p = 0.02) and
poor differentiation (p < 0.01). Testing of the prevalence of PIK3CA mutations and loss of PTEN expression
demonstrated that these two events were independent (p = 0.55).
Conclusion: These data demonstrated the frequent occurrence (34.9%) of PTEN loss of expression in colorectal
cancers, for which gene mutations do not appear to be the main cause. Furthermore, dietary factors are not
associated with loss of PTEN expression. PTEN expression negative CRC were not homogenous, as proximal cancers
were associated with a more advanced Dukes’ stage and poor differentiation, whereas distal cancers were
associated with earlier Dukes’ stage.
Background
The PI3K/AKT signalling pathway affects many cellular
processes including cell proliferation, apoptosis and inva-
sion [1]. Signal transduction through this pathway is
mediated through conversion of phosphatidylinositol
bisphosphate (PIP2) to phosphatidylinositol triphosphate
(PIP3) by phosphatidylinositol 3 kinases (PI3K) following
their activation, and this reaction is antagonised by phos-
phatase and tensin homolog, deleted on chromosome ten
(PTEN) activity. Of the genes which encode the enzy-
matic subunit of PI3K heterodimers, the PIK3CA gene,
encoding the p110∝ protein, has been found to be most
frequently, in not exclusively, mutationally activated in
some human cancers [1,2]. In colorectal cancer (CRC),
PIK3CA activating mutations have been described at fre-
quencies of 10-20% [3-6], with two distinct regions, the
helical and kinase domains, harbouring up to 80% of
mutations [7].
The prevalence of PTEN mutations in CRC has been
reported to vary between 1% and 29% [8-13]. This varia-
bility in observed PTEN mutation frequencies relates to
tumour genomic instability, with PTEN mutations
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having been described in 14-30% of CRC with microsa-
tellite instability (MSI-H) [9,14,15], but at very low fre-
quencies (<5%) in unselected CRC [13]. Exons 7 and 8
of PTEN have been described to acquire more muta-
tions than other regions of the gene in CRC, with inser-
tions and deletions of adenine bases in poly-A tracts
present in these exons being the predominant genetic
change, consistent with frequent changes in repetitive
sequences in MSI-H CRC [15]. Loss of PTEN expression
has been reported at higher frequencies than mutation
[12,15] with approximately 20-40% of CRC exhibiting
loss of PTEN expression [16,17].
Incidence rates of colorectal cancer can vary up to 25-
fold between countries [18] and it has been postulated
that approximately 80% of observed national differences
in incidence between can be attributed to dietary factors
[19]. Although analysis of dietary components has been
performed in relation to general colorectal cancer inci-
dence, their exact relation to specific tumour suppressor
gene losses and signalling pathway alterations remains
to be fully investigated. To date, analysis of dietary fac-
tors in relation to PI3K/AKT pathway component
changes in CRC has not been undertaken and little data
exists describing the type of CRC in which PIK3CA
oncogenic activations and PTEN inactivation occurs.
The present study aimed to investigate the relation-
ship between PTEN and PIK3CA mutations and loss of
PTEN expression in 186 colorectal adenocarcinomas
from the EPIC Norfolk cohort and clinicopathological
features, lifestyle traits and dietary factors, as well as
analysing PTEN expression negative CRC stratified by
stage and tumour location.
Methods
Study population, microsatellite instability analysis,
dietary and lifestyle assessment
Exact descriptions of the study population, case ascer-
tainment, methodology pertaining to dietary and lifestyle
data acquisition and microsatellite instability status
assessment have been described in detail elsewhere [20].
Tissue processing and DNA extraction
Formalin fixed, paraffin embedded human tissue sam-
ples, biopsied from the caecum, proximal colon, distal
colon and rectum, were processed for DNA extraction.
Ten, 4 μm sections were cut from each block using a
Microm HM 325 microtome (Thermo Scientific, Basing-
stoke, UK). A single section of tissue from each block
was stained and used as a template for identification of
adenocarcinoma, adenoma and normal tissue regions
within each sample. To stain, sections underwent four,
15 minute washes: two in xylene followed by 2 in 100%
ethanol. Four, 5 minute sequential washes in 95%, 80%,
70% and 40% ethanol, followed by rinsing in deionised
water, completed the rehydration of the section. The
sections were then immersed in Harris Haematoxylin
Solution (Sigma-Aldrich, Gillingham, UK) for 30 sec-
onds. Sections were then rinsed in tap water and stained
with 1% Eosin Solution (Solmedia, Romford, UK) for 5
seconds. Following a final rinse with tap water to
remove excess stain, cover slips were mounted using
DePeX Mounting Medium Gurr (BDH Laboratory Sup-
plies, Lutterworth, UK). Template slides were analysed
by a consultant gastrointestinal histopathologist (MJA)
using a light microscope and tissue regions correspond-
ing to normal/tumour regions were identified and
marked on the slide. Subsequently, the remaining 9
slides were dehydrated and cells from normal, adenoma
or adenocarcinoma regions were carefully microdis-
sected using a sterile scalpel. Tissue was collected start-
ing 2 mm away from the normal/tumour tissue
boundary, as indicated on the template slide, in order to
minimize collection of non-tumour tissue in adenoma
or adenocarcinoma samples.
DNA extraction
Isolated tissue was digested in 240 μl of Buffer PKD
with 10 μl of Proteinase K (both obtained from RNEasy
kits, QIAGEN, Valencia, USA). Samples were agitated at
150 rpm at 55°C for 4-6 days with the level of tissue
digestion checked after 3 days: those which still had visi-
ble amounts of tissue had a further 10 μl of Proteinase
K added for the remainder of the incubation. Samples
were then incubated at 80°C for 15 minutes in order to
partially reverse formaldehyde modification of the
nucleic acids and to denature any residual protein.
These samples were then used directly, without further
purification, for PCR amplification.
Mutation detection
PTEN exons 7 and 8 were amplified using previously
described primers [10]. PCR products were generated
using 5 ng-2 μg of template DNA. KOD Hot Start DNA
Polymerase kits (Novagen, Madison, USA) were used to
make the following reaction mixture: 2.5 μl ×10 PCR
Buffer for KOD Hot Start DNA Polymerase, 1 μl pri-
mers, forward and reverse (10 μM each), 1 μl MgSO4
(25 mM), 2 μl dNTPs (2 mM each), 0.25 μl KOD DNA
Polymerase and made up to a total reaction volume of
25 μl with nuclease free water (Promega, Madison,
USA). The reactions involved a denaturation step at 94°
C for 5 minutes followed by 45 cycles of 94°C for 15
seconds, then 30 seconds at annealing temperatures of
either 56°C or 54°C for PTEN exons 7 or 8 respectively,
followed by extension at 72°C for 30 seconds. Lastly, a
final extension step of 72°C for 5 minutes was per-
formed. PIK3CA exon 8 was amplified using primers 8F
(5’-CAT AAA TTA GAT ATT TTT TAT GGC AGT
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CAA AC-3’) and 8R (5’-GAG AAA GTA TCT ACC
TAA ATC CAC AGA TTA TAA TTG-3’). PIK3CA
exon 9 was amplified using primers 9F (5’-TTG CTT
TTT CTG TAA ATC ATC TGT G-3’) and 9R (5’-CTG
CTT TAT TTA TTC CAA TAG GTA TG-3’). PIK3CA
exon 20 was amplified using previously described pri-
mers [21]. The PCR was as described above for PTEN
except that annealing temperatures of 55°C were used
for amplification of all three PIK3CA exons. To detect
successful amplifications, 5 μl of each reaction mixture
was separated on a 1.5% agarose gel containing 1 μg/ml
ethidium bromide, and visualised under UV light. The
remaining PCR amplification product mixture (20 μl)
following visualisation on agarose gels was purified
using Multiscreen filter plates (Millipore, Billerica, USA)
according to the manufacturer’s instructions and sub-
jected to direct sequencing by ABI3730xl Platform
sequencer (Applied Biosystems, Warrington, UK). For-
ward and reverse strands were both sequenced. Every
sample was PCR amplified and sequenced independently
a minimum of twice on each strand.
PTEN immunohistochemistry
PTEN protein immunohistochemistry (IHC) was per-
formed using the monoclonal antibody 6H2.1 (Cascade
Biosciences, Winchester, USA). Blocking, addition of
secondary antibody and washing reactions were per-
formed according to the manufacturer’s instructions for
the BondMax staining system with Bond Polymer Refine
Detection Reagents (Leica Microsystems, Wetzlar, Ger-
many). Antigen retrieval was performed for 30 minutes
at 98°C in 0.01 mol/L sodium citrate buffer at pH 6.4.
Primary antibody was applied for 30 minutes at a 1:100
dilution. Secondary antibody was anti-mouse IgG-HRP
(8 μg/ml) and was applied for 15 minutes.
PTEN protein expression was classified as negative if
over 50% of the tumour cells present demonstrated loss
of expression. In order to assess PTEN expression status
in cancer cells, the PTEN expression levels in normal
mucosa on the same slide were used as a reference. Due
to the difference in PTEN staining patterns between
stromal fibroblasts, lymphoid cells and endothelial cells
in the gut, these stromal cells were used only as an
internal control to assess successful IHC staining, not as
a reference for comparison with cancer cell PTEN
expression levels. Instead, non-cancerous mucosa were
used to assess loss of PTEN expression in neoplastic
crypts.
Statistical analysis
Analysis of lifestyle and dietary factors, clinicopathologi-
cal cancer features and patient characteristics was per-
formed using chi-squared (c2) tests for categorical data
and analysis of variance (ANOVA) tests for continuous
numerical data. For these analyses, tumour samples
were classified as PTEN expression positive or negative
and PIK3CA wildtype or mutated (in exons 8, 9 or 20).
For additional testing, PTEN negative adenocarcinomas
were classified by both Dukes’ stage (early: Dukes’ stages
A or B; advanced: Dukes’ stages C or D) and indepen-
dently by tumour location (proximal colonic up to the
splenic flexure, or distal colonic/rectal) and tested for
association with dietary, lifestyle and clinicopathological
factors. Differentiation was determined for all cases by a
consultant histopathologist (MJA) and classified as mod-
erately/well differentiated or poorly differentiated and
cancers were classified as demonstrating either microsa-
tellite instability (MSI) or microsatellite stable (MSS)
status. Lifestyle factors, including smoking status (cur-
rent/former/never), physical activity (high/low), alcohol
consumption (g/day, continuous), low-density lipopro-
tein (mmol/l, continuous) and high-density lipoprotein
(mmol/l, continuous) blood concentrations, triglyceride
blood concentrations (mmol/l, continuous) and plasma
vitamin C concentrations (μmol/l, continuous) were also
tested for association with loss of PTEN expression and
PIK3CA mutations. Continuous dietary variables were
tested for association with PTEN expression status
including meat, fruit and vegetables, fat, vitamin, fibre
and macronutrients, including calcium, in their relevant
unit of consumption. Additionally, PTEN expression
negative adenocarcinomas, categorised by location and
Dukes’ stage, were also tested for associations with diet-
ary factors. A probability value of less than or equal to
0.05 was considered to be statistically significant. No
adjustment was made for multiple testing. All statistical
testing was undertaken using SPSS version 16.0 (SPSS
Inc, Chicago, USA).
Results
PTEN and PIK3CA mutation frequencies and PTEN
expression status in colorectal adenocarcinomas and
adenomas
The type and distribution of the mutations observed in
PTEN and PIK3CA are described in Table 1. Of the 186
adenocarcinoma samples analysed, 4 (2.2%) harboured
PTEN mutations in exons 7 or 8. One sample had muta-
tions in both exons 7 and 8. Three samples showed
mutations in exon 8 only. The mutation in exon 7 was a
C to T transition which resulted in codon 233 of the
protein, arginine (CGA), being converted to a stop
codon (TGA) (Figure 1). This same cancer had a muta-
tion in exon 8: a C to T transition changing codon 339
(CCA) phenylalanine to serine (TCA). The remaining
three cancers harboured changes in PTEN exon 8, all of
which involved changes in the poly-A tract (codons
321-323). These were either a single base deletion or a
single base insertion (Figure 2), shortening the tract
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from 6 to 5, or lengthening the tract from 6 to 7 ade-
nine bases respectively, resulting in a coding frameshift.
The final mutation observed in PTEN exon 8 was a 23
base deletion covering the poly-A tract. This deletion
was from the first base of codon 316 to the second base
of codon 323 inclusive, resulting in a coding frameshift.
None of the 16 adenomas analysed contained mutations
in PTEN exons 7 or 8.
Analysis of PIK3CA exons 8, 9 and 20 demonstrated
that 13 adenocarcinomas (7.0%) harboured mutations
(Table 1). None of the identified mutations were in
PIK3CA exon 8. Eight cancer samples possessed muta-
tions in exon 9 and 5 cancers showed mutations in
exon 20. In addition to the five non-synonymous base
changes observed in exon 20, four synonymous SNPs
were also detected in this exon. All four were the same,
Table 1 The type and distribution of mutations in PTEN exons 7 and 8 and PIK3CA exons 8, 9 and 20 in 186
adenocarcinoma and 16 adenoma samples available from EPIC Norfolk.
PTEN mutations in exons 7 and 8
Mutations in adenocarcinomas Mutations in adenomas Total
Codon 233: wildtype CGA*
TGA (Arg to Stop) 1 0 1
Codon 339: wildtype CCA*
TCA (Phe to Ser) 1 0 1
Poly-A tract (codons 321-323)
1 bp insertion 1 0 1
Poly-A tract (codons 321-323)
1 bp deletion 1 0 1
Codon 316 (1st base) to 323 (2nd base)
23 bp deletion 1 0 1
Total 5 0 5
PIK3CA mutations in exons 8, 9 and 20
Mutations in adenocarcinomas Mutations in adenomas Total
Codon 542: wildtype GAA
GTA (Glu to Val) 1 0 1
AAA (Glu to Lys) 2 0 2
Codon 545: wildtype GAG
AAG (Glu to Lys) 2 1 3
Codon 546: wildtype CAG
AAG (Gln to Lys) 2 0 2
CGG (Gln to Arg) 1 0 1
Codon 1046: wildtype CAT
CGT (His to Arg) 5 0 5
Total 13 1 14
*These two mutations were observed in the same adenocarcinoma.
233
Figure 1 Mutation observed in PTEN exon 7 . Codon 233
encoding arginine (CGA), is changed to a stop codon (TGA),
resulting in truncation of the PTEN protein.
poly-A tract
Figure 2 Single base insertion in the poly-A tract of PTEN exon
8. A frameshift mutation in the PTEN gene caused by the single
insertion of an additional adenine base in the poly-A tract of exon 8.
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previously reported, SNP (rs17849079) that changes
codon 1025 to ACT instead of ACC: both codons
encode threonine. Of the 16 adenoma samples tested
for mutation, one (6.3%) harboured a mutation in
PIK3CA in exon 9. This single PIK3CA mutated ade-
noma presented in an individual as an isolated neo-
plasm, without concurrent adenocarcinoma.
PTEN expression data were obtained for 172 adeno-
carcinomas. No data were obtained for 14 samples due
to lack of tissue, poor sample fixation or non-interpreta-
ble immunohistochemical staining due to technical pro-
blems. Of these 172 samples, 60 (34.9%) demonstrated
loss of PTEN expression (Figures 3 and 4). All four ade-
nocarcinomas with PTEN mutations demonstrated loss
of PTEN expression. Expression data were available for
14 adenoma samples, 2 (14.3%) of which demonstrated
loss of PTEN expression. One of the adenomas demon-
strating negative PTEN expression presented in isolation
in the absence of an adenocarcinoma, whereas the sec-
ond adenoma presented with a coincident adenocarci-
noma. However, negative PTEN expression was only
identified in the adenoma, not in the separate cancer
obtained from the same individual.
Lifestyle and clinicopathological factors in relation to
PTEN expression and PIK3CA mutation
Analysis of the distribution of cancers with loss of
PTEN expression and PIK3CA mutations according to
clinicopathological and lifestyle variables is presented in
Table 2. Stratification of clinicopathological and lifestyle
variables by PTEN mutation status in isolation was not
performed due to the small number of samples demon-
strating a mutated PTEN genotype in exons 7 and 8.
Individuals with cancers lacking PTEN expression exhib-
ited significantly lower mean blood LDL concentrations
than those with cancers demonstrating normal PTEN
expression (p = 0.05): 3.90 mmol/l versus 4.28 mmol/l.
Testing of PIK3CA mutation status according to lifestyle
and clinicopathological factors demonstrated an
increased prevalence of PIK3CA mutations in females
with CRC (p = 0.04).
Figure 3 PTEN immunohistochemistry of an invasive
adenocarcinoma [Inv.Aden.] and adjacent adenoma [Adenoma]
which demonstrates altered PTEN expression. Both adenoma
and adenocarcinoma are surrounded by lymphoid and stromal cells
which are expressing PTEN. The normal stromal cells exhibit strong
nuclear and cytoplasmic staining. The adenoma cells appear to have
reduced nuclear but retained cytoplasmic staining, whereas the
invasive cancer cells have lost both nuclear and cytoplasmic PTEN
expression (×200).
Figure 4 Immunohistochemical analysis showing loss of PTEN
expression in a colorectal adenocarcinoma. A: Colorectal
adenocarcinoma showing loss of PTEN expression by
immunohistochemistry (×100). The cancer cells show lack of
expression, whereas stromal lymphoid and fibroblastic cells
demonstrate high levels of PTEN expression in the nucleus with
reduced but evident cytoplasmic staining. B: A different region of
the same adenocarcinoma magnified (×200) to reveal some foci of
entrapped non-cancerous epithelial cells [N.C.] showing PTEN
expression in both nuclear and cytoplasmic compartments with
weaker expression in their nuclei comparative to the nuclei of
lymphoid and stromal cells.
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Dietary factors and PTEN expression in CRC
None of the dietary variables tested displayed a statisti-
cally significant association with cancers positively or
negatively expressing PTEN (Table 3). Testing of
PIK3CA mutation status according to dietary consump-
tions was not performed due to the calculated low
power of such testing as <10% of cases demonstrated
mutations in the three PIK3CA exons analysed.
PTEN expression negative cancers stratified by Dukes’
stage and tumour location
In order to assess the significance of Dukes’ stage and
colorectal location relative to PTEN expression, cancers
lacking PTEN expression were stratified by these char-
acteristics (Table 4). Cancers demonstrating loss of
PTEN expression and of a less advanced Dukes’ stage
(A/B) were more frequently located in the distal colon
Table 2 Clinicopathological and lifestyle characteristics of colorectal cancer cases by stratified PTEN expression and
PIK3CA mutation status
PTEN expression status PIK3CA mutation status
Characteristic Positive Negative P‡ Wildtype Mutant P‡
n = 112† n = 60† n = 172† n = 13†
Sex
Male 48.2 (54) 46.7 (28) 52.0 (90) 23.1 (3)
Female 51.8 (58) 53.3 (32) 0.85 48.0 (83) 76.9 (10) 0.04
Age at diagnosis (years) 71.0 (7.5) 70.0 (8.0) 0.43* 70.3 (7.7) 73.3 (5.6) 0.17*
Tumour location
Proximal colonic 34.0 (35) 42.9 (24) 34.4 (55) 53.8 (7) (FET)
Distal colonic/Rectal 66.0 (68) 57.1 (32) 0.27 65.6 (105) 46.2 (6) 0.23
Differentiation
Well/Moderate 86.9 (86) 87.0 (47) 84.9 (129) 92.3 (12) (FET)
Poor 13.1 (15) 13.0 (7.0) 0.98 15.1 (23) 7.7 (1) 0.69
Dukes’ Stage
A/B 53.6 (52) 55.8 (29) 54.4 (80) 61.5 (8)
C/D 46.4 (45) 44.2 (23) 0.80 45.6 (67) 38.5 (5) 0.62
MSI status
MSS 83.0 (88) 83.3 (45) 84.6 (126) 63.6 (7) (FET)
MSI 17.0 (18) 16.7 (9) 0.96 15.4 (23) 36.4 (4) 0.09
BMI (kg/m2) 27.3 (4.1) 26.6 (4.4) 0.36* 27.3 (4.3) 25.7 (4.4) 0.20*
Alcohol consumption 9.7 (16) 6.6 (9.7) 0.17* 9.5 (15.0) 5.4 (10) 0.34*
Smoking status
Current 12.0 (13) 8.3 (5) 11.2 (19) 0.0 (0)
Former 46.3 (50) 45.0 (27) 45.6 (77) 58.3 (7)
Never 41.7 (45) 46.7 (28) 0.69 43.2 (73) 41.7 (5) 0.42
Physical activity
Low 64.3 (72) 70.0 (42) 65.7 (113) 84.6 (11) (FET)
High 35.7 (40) 30.0 (18) 0.45 34.3 (59) 15.4 (2) 0.23
HRT status
Current 10.3 (6) 6.5 (2) 9.8 (8) 0.0 (0)
Former 17.2 (10) 16.1 (5) 17.1 (14) 20.0 (2)
Never 72.4 (42) 77.4 (24) 0.81 73.2 (60) 80.0 (8) 0.58
LDL cholesterol (mmol/l) 4.28 (1.2) 3.90 (1.1) 0.05* 4.12 (1.1) 4.30 (1.0) 0.61*
HDL cholesterol (mmol/l) 1.31 (0.4) 1.30 (0.4) 0.96* 1.30 (0.4) 1.29 (0.4) 0.93*
Triglyceride (mmol/l) 1.99 (0.8) 2.25 (1.6) 0.17* 2.09 (1.1) 2.11 (1.5) 0.95*
Plasma vitamin C (μmol/l) 50.3 (18) 53.3 (33) 0.47* 51.2 (24) 54.1 (19) 0.71*
‡P values determined by c2 test or Fisher’s exact test when one or more expected values were less than 5 (denoted by FET). *: ANOVA tests used to calculate p-
values. Results presented as % (n) or mean (±SD). HRT: hormone replacement therapy. MSI: Microsatellite instability. MSS: Microsatellite stable. † Not all
individuals had data for each variable, in these cases these individuals were omitted from the test. PTEN expression data were available for 172 cases. For HRT
testing only females were analysed.
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or rectum; whereas cancers demonstrating loss of PTEN
expression and advanced Dukes’ stage (C/D) were more
frequently located in the proximal colon (p = 0.02).
Additionally, cancers of all stages located in the proxi-
mal colon lacking PTEN expression were more fre-
quently poorly differentiated than those that were in the
distal colon or rectum (p < 0.01).
All dietary factors were tested for association with
PTEN expression negative cancers stratified by Dukes’
stage and colorectal location. Advanced stage (Dukes’ C
and D) cancers demonstrating loss of PTEN expression
were associated with a higher consumption of non-
starch polysaccharides than those PTEN expression
negative cancers which were of a less advanced stage
(Dukes’ A and B) (p = 0.01). No other dietary variables
tested displayed a statistically significant association
with either early or advanced Dukes’ stage, PTEN
expression negative cancers or proximal colonic or distal
colonic/rectally located PTEN negative cancers.
Mutations in PTEN and PIK3CA and loss of PTEN
expression in relation to BRAF and K-RAS mutations
In a previous analysis performed in our laboratory, the
186 colorectal adenocarcinomas and 16 adenomas
described in this report were tested for the presence of
BRAF and K-RAS mutations [20]. In order to assess any
relationship between oncogenic activation or loss of
tumour suppressor function in the PI3K/AKT and
MAPK/ERK signalling pathways, mutations in PIK3CA,
PTEN, BRAF and K-RAS, as well as loss of PTEN
expression, were tested in relation to each other (Table
5). Our previous analyses demonstrated that within the
186 adenocarcinomas tested, BRAF and K-RAS muta-
tions occurred together less frequently than expected by
chance (c2 test, p = 0.009). Further analysis demon-
strated that PTEN exon 7 and 8 and PIK3CA exon 8, 9
and 20 mutations were not related in either a mutually
exclusive or a co-occurring manner (Fisher’s exact test,
p = 0.25). PIK3CA mutations and PTEN loss of expres-
sion were also not related (Fisher’s exact test, p = 0.55).
Further tests showed that PTEN mutations and BRAF
mutations were associated (Fisher’s exact test, p < 0.001)
and both were associated with MSI (BRAF: p < 0.001,
PTEN: Fisher’s exact test p = 0.01). Of the four adeno-
carcinomas which exhibited mutations in PTEN exons 7
and 8, all also harboured BRAF mutations. Analysis of
PTEN loss of expression and BRAF mutations did not
demonstrate co-occurrence (c2 test, p = 0.80). K-RAS
mutations were not linked to either mutations of either
PIK3CA or PTEN or loss of PTEN expression. Due to
the low number of adenomas available for analysis, test-
ing for the co-incidence of mutations in several genes
was not performed these pre-cancerous lesions.
Discussion
The data presented confirm that loss of PTEN expres-
sion occurs in a significant proportion (35%) of colorec-
tal cancers and may be due to mutation in only a
minority of cases. Loss of PTEN expression has pre-
viously been reported at higher rates than mutation in
colorectal cancer [12,15]. Loss of PTEN expression is
associated with different clinicopathological features,
including cancer stage and position in the bowel. How-
ever, loss of PTEN expression does not appear to be
associated with any particular dietary factors. Mutations
in PIK3CA were observed at a lower prevalence (7%)
than loss of PTEN expression.
Our observation of approximately one third of cancers
demonstrating loss of PTEN expression is in keeping
with other reports which have identified 20-40% of CRC
Table 3 Dietary intakes stratified by PTEN expression
PTEN expression status
Dietary factor Positive n =
112
Negative n =
60
P‡
Meat
Red Meat (g/d) 36 (27.1) 39 (30.3) 0.56
Processed Meat (g/d) 26 (19.2) 24 (19.5) 0.60
Red + Processed Meat
(g/d)
62 (37.3) 63 (34.1) 0.86
White Meat (g/d) 19 (18.7) 21 (18.2) 0.49
White Fish (g/d) 17 (19.5) 16 (14.0) 0.59
Fatty Fish (g/d) 12 (21.8) 10 (13.7) 0.38
Fruit and vegetables
Fruit (g/d) 177 (144.1) 163 (125.0) 0.53
Vegetables (g/d) 135 (73.1) 140 (60.0) 0.63
Fat
Total Fat (g/d) 70 (22.9) 73 (22.2) 0.31
PUFA (g/d) 13 (5.4) 14 (5.2) 0.50
MUFA (g/d) 24 (8.1) 26 (7.9) 0.12
SFA (g/d) 27 (10.3) 28 (9.8) 0.53
Vitamins
B2[riboflavin] (mg/d) 2 (0.6) 2 (0.6) 0.91
B3[niacin] (mg/d) 18 (5.4) 18 (6.3) 0.56
B6[pyroxidine] (μg/d) 2 (0.6) 2 (0.6) 0.76
B9[folate] (μg/d) 257 (73.3) 260 (69.2) 0.79
B12 (μg/d) 6 (5.6) 5 (3.7) 0.29
C (mg/d) 85 (49.0) 84 (44.8) 0.85
D (μg/d) 3 (2.2) 3 (2.2) 0.99
Fibre and Macronutrients
Total Energy (MJ/d) 8 (2.1) 8.0 (1.9) 0.38
Carbohydrate (g/d) 230 (65.4) 245 (67.9) 0.17
Protein (g/d) 70 (15.1) 70 (14.3) 0.97
NSP (g/d) 14 (5.7) 15 (5.3) 0.44
Calcium (mg/d) 773 (239.2) 795 (220.1) 0.55
‡P values determined by ANOVA. Results presented as mean (±SD). PUFA:
polyunsaturated fatty acid. MUFA: monounsaturated fatty acid. SFA: saturated
fatty acid. NSP: non-starch polysaccharide. PTEN expression data were
available for 172 cases.
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as PTEN expression negative [16,17], as is our observa-
tion of low PTEN mutation rates that have been
reported in previous studies. One study of 72 unselected
colorectal cancers analysing all 9 exons of PTEN identi-
fied a mutation frequency of 1.4% [13]. Two studies,
both analysing 32 microsatellite unstable colorectal can-
cers, identified PTEN mutation frequencies of 18.8%
[14] and 14.0% [15] in MSI+ CRC. As approximately
15% of all colorectal cancers display microsatellite
instability [22], these data suggest that in an unselected
sample set, if PTEN mutation is found predominantly or
entirely in MSI+ colorectal cancers, approximately 2-3%
of all colorectal cancer samples may be expected to
exhibit PTEN mutations. Our data corroborate this
estimation.
Of the adenocarcinomas tested in this report, 17.1%
were classified as microsatellite unstable [20] and of
these MSI+ cases, 4 (13.8%) harboured PTEN mutations,
a figure consistent with previously published observa-
tions [14]. Statistical testing of the distribution of PTEN
mutations and MSI demonstrated a positive association
between these two features (FET, p = 0.01). Although
testing of greater numbers of PTEN mutant samples is
required to validate these observations, these data show
that MSI and PTEN mutations, in exons 7 and 8 at
least, occur together in the same colorectal cancers,
along with BRAF mutations. This association is consis-
tent with the type of PTEN mutations observed in our
analyses. Three of the four observed mutations were
repetitive sequence insertions or deletions involving the
Table 4 Clinicopathological and lifestyle characteristics of PTEN expression negative colorectal cancers stratified by
Dukes’ stage and colorectal location
PTEN expression negative colorectal adenocarcinomas
Characteristic Dukes’ stage A/B
n = 29†
Dukes’ stage C/D
n = 23†
P‡ Proximal colonic
n = 24†
Distal colonic/Rectal
n = 32†
P‡
Sex
Male 58.6 (17) 39.1 (9) 41.7 (10) 46.9 (15)
Female 41.4 (12) 60.9 (14) 0.16 58.3 (14) 53.1 (17) 0.70
Age at diagnosis (years) 70.3 (8.14) 69.0 (8.67) 0.56 71.0 (7.31) 69.1 (8.77) 0.41
Tumour location
Proximal colonic 37.5 (9) 72.0 (18) a a
Distal colonic/Rectal 62.5 (15) 28.0 (7) 0.02 a a a
Differentiation
Well/Moderate 92.6 (25) 78.3 (18) (FET) 69.6 (16) 100.0 (28) (FET)
Poor 7.4 (2) 21.7 (5) 0.23 30.4 (7) 0.0 (0) <0.01
Dukes’ Stage
A/B a a 37.5 (9) 72.0 (18)
C/D a a a 62.5 (15) 28.0 (7) 0.02
MSI status
MSS 81.5 (22) 84.2 (16) (FET) 72.7 (16) 89.7 (26) (FET)
MSI 18.5 (5) 15.8 (3) 1.00 27.3 (6) 10.3 (3) 0.15
BMI (kg/m2) 26.2 (3.60) 26.4 (4.77) 0.85 26.5 (4.71) 26.4 (3.64) 0.93
Alcohol consumption 6.6 (11.1) 6.5 (7.8) 0.97 4.0 (5.7) 8.0 (10.8) 0.11
Smoking status
Current 13.8 (4) 4.3 (1) 8.3 (2) 9.4 (3)
Former 41.4 (12) 52.2 (12) 54.2 (13) 40.6 (13)
Never 44.8 (13) 43.5 (10) 0.47 37.5 (9) 50.0 (16) 0.60
Physical activity
Low 69.0 (20) 65.2 (15) 58.3 (14) 78.1 (25)
High 31.0 (9) 34.8 (8) 0.78 41.7 (10) 21.9 (7) 0.11
LDL cholesterol (mmol/l) 3.70 (1.05) 3.94 (1.11) 0.45 3.82 (1.17) 3.97 (0.98) 0.62
HDL cholesterol (mmol/l) 1.29 (0.39) 1.33 (0.50) 0.76 1.30 (0.51) 1.34 (0.36) 0.69
Triglyceride (mmol/l) 1.90 (1.21) 2.75 (1.95) 0.06 2.48 (1.61) 1.97 (1.35) 0.21
Plasma vitamin C (μmol/l) 46.6 (18.9) 52.7 (23.1) 0.32 48.1 (19.5) 56.6 (40.1) 0.37
‡P values determined by c2 test or Fisher’s exact test when one or more expected values were less than 5 (denoted by FET). *: ANOVA tests used to calculate p-
values. Results presented as % (n) or mean (±SD). HRT: hormone replacement therapy. MSI: Microsatellite instability. MSS: Microsatellite stable. † Not all
individuals had data for each variable, in these cases these individuals were omitted from the test. HRT status was not analysed due to the low numbers of cases
available for testing. a Testing of Dukes’ stage in relation to cancer location in the bowel is presented once per test set.
Naguib et al. BMC Cancer 2011, 11:123
http://www.biomedcentral.com/1471-2407/11/123
Page 8 of 11
poly-A tracts in PTEN, consistent with mismatch repair
deficiency, which is the cause of MSI in cancers. Loss of
PTEN expression in general, unlike PTEN mutation, was
not linked to MSI.
It has been reported that the majority of PTEN muta-
tions in CRC may occur in exons 7 and 8 [15], which in
our cohort harboured mutations in only 2.2% of CRC
samples, in keeping with published studies [13]. Follow-
ing this, we performed an immunohistochemical (IHC)
analysis of PTEN protein expression as there are advan-
tages of such an approach. First, IHC analysis of tissue
samples circumvents the requirement for PCR based
sequencing analyses of all 9 exons of PTEN or of the
analysis of PTEN cDNA, which is identical to the non-
translated transcript of the PTEN pseudogene except for
18 bp [23]. Second, expression analysis by IHC allows
for all factors, including mutation, promoter methyla-
tion, miRNA alterations or PTEN gene copy number
changes, that affect PTEN protein expression levels in
colorectal tumours, to be assessed in one assay with
direct comparison of normal, adenoma and adenocarci-
noma cells. Third, this integrative assay identified a
large enough group of CRCs with abnormal PTEN activ-
ity and presence to allow meaningful statistical testing of
associations with dietary and lifestyle factors.
Loss of PTEN protein expression may be explained by
several mechanisms in addition to mutation. CpG island
methylator phenotype (CIMP), resulting in silencing of
expression of affected genes occurs in 10-20% CRC [24].
Methylation at the PTEN locus (10q23) may be respon-
sible for loss of expression observed in some of the CRC
lacking PTEN mutations; an observation previously
described in MSI CRC [11]. Additionally, chromosomal
instability (CIN) leading to loss of heterozygosity (LOH)
at 10q23 may also have contributed to the loss of PTEN
expression observed, as LOH at 10q23 has been docu-
mented in 20-30% of colorectal cancers [12,15,25].
Analysis of clinicopathological cancer features and
dietary and lifestyle factors relative to PTEN expression
status demonstrated no associations with PTEN expres-
sion except in the case of blood low-density lipoprotein
(LDL) levels. Individuals with cancers exhibiting loss of
PTEN expression demonstrated lower mean blood LDL
concentrations than individuals with colorectal cancers
retaining PTEN expression (p = 0.05). Lower blood LDL
levels may correlate with a generally more healthy diet
and lifestyle, but the relevance of this observation is
unclear and would benefit from further investigation.
PIK3CA mutations in exons 8, 9 and 20 were observed
in 7.0% of cancers. This frequency is at the lower end of
the range of previously reported frequencies of 10-20%
[3-6] and may be due to the restricted region of analysis
used (exons 8, 9 and 20). It has been reported that 70-
80% of all PIK3CA mutations are located in the helical
and kinase domains in these 3 exons [2,3,7] and as such,
restricting analysis to these regions may have led to
some mutations in other exons not being identified. In
our previous analyses we also observed that 22% of the
cancers in our study cohort possessed K-RAS mutations,
including a previously unreported double mutation in
codons 19 and 20 [20,26]. This frequency is lower than
the 30-40% expected prevalence for mutations in this
gene. Several observations suggest that these low muta-
tion frequencies are accurate for this CRC cohort and
not the result of technical shortcomings. First, our pre-
vious analysis of BRAF mutations in this same sample
set demonstrated a higher than expected prevalence of
this mutation (15.9%). Secondly, our analyses identified
that 17% of the tumours in our dataset demonstrated an
MSI phenotype, a level slightly above the expected
~15% prevalence of microsatellite instability in CRC
[22]. As the same DNA samples were used across all
Table 5 The distribution of PTEN, PIK3CA, BRAF and K-
RAS mutations and loss of PTEN expression in the 186
adenocarcinomas available from EPIC Norfolk.
BRAF mutant BRAF wildtype
K-RAS mutant 3.4 (1) 25.5 (40)
K-RAS wildtype 96.6 (28) 74.5 (117) p = 0.009
BRAF mutant BRAF wildtype
PTEN mutant 13.8 (4) 0.0 (0) (FET)
PTEN wildtype 86.2 (25) 100.0 (157) p < 0.001
BRAF mutant BRAF wildtype
PTEN expression negative 37.0 (10) 34.5 (50)
PTEN expression positive 63.0 (17) 65.5 (95) p = 0.80
BRAF mutant BRAF wildtype
PIK3CA mutant 13.8 (4) 5.7 (9) (FET)
PIK3CA wildtype 86.2 (25) 94.3 (148) p = 0.12
K-RAS mutant K-RAS wildtype
PIK3CA mutant 7.3 (3) 6.9 (10) (FET)
PIK3CA wildtype 92.7 (38) 93.1 (135) p = 1.00
K-RAS mutant K-RAS wildtype
PTEN mutant 0.0 (0) 2.8 (4) (FET)
PTEN wildtype 100.0 (41) 97.2 (141) p = 0.58
K-RAS mutant K-RAS wildtype
PTEN expression negative 41.7 (15) 33.1 (45)
PTEN expression positive 58.3 (21) 66.9 (91) p = 0.34
PIK3CA mutant PIK3CA wildtype
PTEN expression negative 23.1 (3) 35.8 (57) (FET)
PTEN expression positive 76.9 (10) 64.2 (102) p = 0.55
PIK3CA mutant PIK3CA wildtype
PTEN mutant 7.7 (1) 1.7 (3) (FET)
PTEN wildtype 92.3 (12) 98.3 (170) p = 0.25
P values determined by c2 test or Fisher’s exact test when one or more
expected values were less than 5 (denoted by FET). Results presented as %
(n). PTEN expression data were not available for 12/186 colorectal
adenocarcinomas: these cases were omitted from testing.
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analyses, these observations suggest that the observed
low mutation frequencies in PIK3CA and K-RAS are a
characteristic of this study cohort.
Fewer than 10% of samples demonstrated PIK3CA
mutations, therefore analysis of dietary factors was not
performed due to the calculated low power of the statis-
tical testing. PIK3CA mutations were more frequent in
CRC from females (p = 0.04). This has been demon-
strated previously in another report analysing a Cauca-
sian European population (Italian) [4], but not in a
study of a Middle Eastern population [3]. These discre-
pancies in analyses of different population types may
suggest a correlation between local environment, diet
and PIK3CA mutation.
Analysis of PTEN expression negative tumours strati-
fied by location demonstrated that proximally located
cancers were more frequently of advanced Dukes’ stage
and distal colonic/rectal cancers were more frequently
of less advanced Dukes’ stage (p = 0.02). Additionally,
proximal cancers lacking PTEN expression were asso-
ciated with poor differentiation (p < 0.01). Stratification
of PTEN negative cancers by stage and location also
identified an increased mean non-starch polysaccharide
consumption in those individuals with advanced stage
cancers lacking PTEN expression (p = 0.01). This poten-
tially interesting observation requires confirmation in
future larger studies. Taken together, these data demon-
strate the heterogeneity in the associations of cancers
lacking PTEN expression: loss of PTEN expression in
colorectal cancers of different locations have distinct
clinicopathological features and potential dietary
associations.
Analysis of co-occurrences of mutations in the PI3K
and MAPK signalling pathways demonstrated that
unlike BRAF and K-RAS mutations, acting as mutually
exclusive mechanisms of activation of the same signal-
ling pathway, oncogenic PIK3CA activation and PTEN
loss are not equivalent. These two events share limited
redundancy, indicating that both provide independent
growth advantages for cancer cells. Mutations in BRAF
and PTEN were associated: four adenocarcinomas had
PTEN mutations, mostly in poly-A tracts, and all 4 CRC
were MSI+ and proximally located, typical of defective
DNA mismatch repair tumours.
A strength of the current study is the use of prospec-
tive data collected before disease onset, as well as
employment of 7-day diaries for dietary assessment, a
method shown to estimate diet more accurately than
food frequency questionnaires [27]. This report greatly
expands the limited current data describing alterations
in PI3K/AKT pathway components in colorectal cancer
and dietary intakes. Adjustment for confounding vari-
ables in the statistical testing was not performed. Such
testing using logistic regression methods, performed on
low sample sets has been described to lead to systematic
bias (i.e. away from null), and overestimation of odds
ratios [28]. In order to prevent overestimation of dietary
risk factors, this testing was not performed on the rela-
tively small sample sizes available.
This report is one of the first to analyse PTEN and
PIK3CA mutation and PTEN expression in colorectal
adenomas, albeit in a low number of cases. PIK3CA was
mutated in a single adenoma (6.3%). Two adenomas
(14.3%) demonstrated loss of PTEN expression. These
data demonstrate that PIK3CA mutation and loss of
PTEN expression can occur during adenoma formation.
This confirms previous data describing PIK3CA muta-
tions in adenomas [2,29]. This report is one of the first
to analyse PTEN expression in colorectal adenomas.
However, the small sample size indicates that the find-
ings should be interpreted with caution.
Conclusions
This study is one of the largest to date analysing PTEN
expression in colorectal cancers, showing association of
this with Dukes’ stage and colorectal location, indicating
a worse prognosis of PTEN expression negative cancers
of the proximal colon that show poor differentiation
and advanced Dukes’ stage. Furthermore, mutations in
the PTEN gene, although likely to be rare in unselected
colorectal cancers, are associated with MSI+ and BRAF
mutations, whereas loss of PTEN expression is not and
may be due mostly to other mechanisms. These data
describe the assessment of associations between dietary
factors and loss of PTEN expression in colorectal can-
cers, suggesting that general loss of PTEN expression is
independent of any specific dietary influences. Further-
more, increased signalling mediated by the PI3K/AKT
pathway, achieved via mutations in PIK3CA or loss of
PTEN expression are not mutually exclusive, suggesting
that independent growth advantages are provided by
these two cancer promoting changes in colorectal
cancer.
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